Home › Trial NCT01083615
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Trial IDNCT01083615
- StatusTerminated
- PhasePhase 3
- Study typeInterventional
- SponsorAchieve Life Sciences
- Enrollment14
- Start date2010-03
- ConditionsCastrate-Resistant Prostate Cancer · Hormone Refractory Prostate Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.